The goal of this clinical trial is to assess the effectiveness of full-body blue light irradiations in the treatment of inflammatory skin diseases (atopic dermatitis, psoriasis, eczema) and chronic pruritus in adult and pediatric populations. The main questions it aims to answer are: * If blue light irradiations have an impact on the improvement in skin condition * If blue light irradiations affect the patients' quality of life * If blue light irradiations decrease pruritus Participants will: * Be administered phototherapeutic blue light (453 nm) for 15 minutes to each side of the body (30 minutes in total), 3-5 times per week. The study is scheduled for a maximum of 60 irradiations of blue light. * Complete the Dermatology Life Quality Index questionnaire and a 10-item pruritus severity scale * Be assessed using dermatologic scales * Have blood samples collected
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Statistically significant change in PASI (Psoriasis Area Severity Index) score of the patients after blue light irradiation
Timeframe: From the date of the first irradiation (visit 1) until the cessation of therapy, up to 25 weeks. In case of earlier cessation of therapy, the evaluation will be conducted at the last visit and then 4 weeks after the cessation of therapy.
Statistically significant change in PGA (Physician's Global Assessment) score of the patients after blue light irradiation
Timeframe: From the date of the first irradiation (visit 1) until the cessation of therapy, up to 25 weeks. In case of earlier cessation of therapy, the evaluation will be conducted at the last visit and then 4 weeks after the cessation of therapy.
Statistically significant change in VAS (Visual Analogue Scale) score of the patients after blue light irradiation
Timeframe: From the date of the first irradiation (visit 1) until the cessation of therapy, up to 25 weeks. In case of earlier cessation of therapy, the evaluation will be conducted at the last visit and then 4 weeks after the cessation of therapy.
Statistically significant change in 10-item Pruritus Severity Scale score of the patients after blue light irradiation
Timeframe: From the date of the first irradiation (visit 1) until the cessation of therapy, up to 25 weeks. In case of earlier cessation of therapy, the evaluation will be conducted at the last visit and then 4 weeks after the cessation of therapy.
Statistically significant change in IGA (Investigators' Global Assessment) score of the patients after blue light irradiation
Timeframe: From the date of the first irradiation (visit 1) until the cessation of therapy, up to 25 weeks. In case of earlier cessation of therapy, the evaluation will be conducted at the last visit and then 4 weeks after the cessation of therapy.
Statistically significant change in SCORAD (SCORing Atopic Dermatitis) score of the patients after blue light irradiation
Timeframe: From the date of the first irradiation (visit 1) until the cessation of therapy, up to 25 weeks. In case of earlier cessation of therapy, the evaluation will be conducted at the last visit and then 4 weeks after the cessation of therapy.
Statistically significant change in EASI (Eczema Area Severity Index) score of the patients after blue light irradiation
Timeframe: From the date of the first irradiation (visit 1) until the cessation of therapy, up to 25 weeks. In case of earlier cessation of therapy, the evaluation will be conducted at the last visit and then 4 weeks after the cessation of therapy.
Statistically significant (p <0.05) change in DLQI (Dermatology Life Quality Index)
Timeframe: From the date of the first irradiation (visit 1) until the cessation of therapy, up to 25 weeks. In case of earlier cessation of therapy, the evaluation will be conducted at the last visit and then 4 weeks after the cessation of therapy.